Ascendiant Capital Markets Forecasts Cingulate Q3 Earnings

Cingulate Inc. (NASDAQ:CING) – Ascendiant Capital Markets cut their Q3 2026 earnings per share estimates for Cingulate in a report issued on Wednesday, August 19th. Ascendiant Capital Markets analyst E. Woo now expects that the company will post earnings of ($0.39) per share for the quarter, down from their prior forecast of ($0.33). Ascendiant Capital Markets currently has a “Buy” rating and a $52.00 target price on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($2.39) per share. Ascendiant Capital Markets also issued estimates for Cingulate’s Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($2.04) EPS, Q1 2027 earnings at ($0.40) EPS, Q3 2027 earnings at ($0.33) EPS, Q4 2027 earnings at ($0.29) EPS and FY2027 earnings at ($1.38) EPS.

Other equities analysts have also recently issued reports about the stock. Wall Street Zen raised shares of Cingulate from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Roth Capital set a $9.00 price objective on shares of Cingulate and gave the stock a “buy” rating in a research report on Sunday. Weiss Ratings cut shares of Cingulate from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Cingulate in a report on Tuesday, May 26th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $27.00.

Cingulate Stock Performance

NASDAQ CING opened at $5.68 on Tuesday. The stock has a market capitalization of $82.60 million, a price-to-earnings ratio of -1.58 and a beta of -0.90. The stock’s 50 day moving average price is $4.99 and its two-hundred day moving average price is $5.57. Cingulate has a 52 week low of $3.16 and a 52 week high of $11.89.

Cingulate (NASDAQ:CING) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.18.

Institutional Trading of Cingulate

Several institutional investors and hedge funds have recently bought and sold shares of CING. Bank of America Corp DE grew its stake in Cingulate by 283.1% in the second quarter. Bank of America Corp DE now owns 7,501 shares of the company’s stock valued at $31,000 after purchasing an additional 5,543 shares in the last quarter. Soltis Investment Advisors LLC acquired a new position in shares of Cingulate during the 4th quarter worth approximately $43,000. XTX Topco Ltd acquired a new position in shares of Cingulate during the 2nd quarter worth approximately $45,000. Quadrature Capital Ltd bought a new stake in shares of Cingulate during the 4th quarter worth approximately $66,000. Finally, Chicago Partners Investment Group LLC bought a new stake in shares of Cingulate during the 1st quarter worth approximately $116,000. Institutional investors own 41.31% of the company’s stock.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.